On October 11th, Prof. Sergio Bernardini, Secretary General of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), visited Wondfo, expressing his recognition of the company’s scientific innovation capabilities. During the visit, both sides signed an agreement to foster international cooperation in medical diagnostics innovation and academic research, working together to advance laboratory medicine and protect global health.

Prof. Bernardini, Secretary General of the IFCC, is a distinguished expert in laboratory medicine, focusing on clinical molecular biology, pediatric science, and clinical biochemistry. He is a full-time professor at the University of Rome Tor Vergata and serves as the Director of Clinical Molecular Biology at the university’s affiliated hospital. With extensive theoretical research and practical clinical experience, he is highly regarded in the international medical community.
 
During his visit to Wondfo’s R&D and manufacturing base in Guangzhou, Prof. Bernardini gained in-depth insights into the company’s innovation system and lean manufacturing system. He praised Wondfo’s strengths in areas such as rapid diagnostics, critical care diagnostics, and smart healthcare systems. Prof. Bernardini expressed great interest in Wondfo's self-developed TLT (thromboelastography) device for coagulation testing, "Its application in operating rooms and emergency departments will play a key role in pre-, intra-, and post-operative monitoring," he noted. "There are few companies offering such products on the market, and it holds great potential."
 

In response to the growing demand for digital diagnostics, Wondfo has developed an advanced intelligent management system for the POCT field. enabling real-time quality control, digital data management, and visualized monitoring. "This type of system will greatly enhance data management capabilities and real-time monitoring efficiency across diverse applications in Europe, such as central laboratories, hospital departments, and pharmacies," Prof. Bernardini affirmed, emphasizing the potential to significantly improve operational efficiency.
 
On the same day, Prof. Bernardini and Wondfo signed a partnership agreement. Moving forward, both sides will focus on multiple areas cooperation, including academic exchanges, product development, and product evaluation in in-vitro diagnostics. "I look forward to deepening our cooperation,"Prof. Bernardini remarked, expressing his hope that the partnership will promote the widespread application of high-quality products across Europe and globally, benefiting more patients.
 

As a global organization in clinical chemistry and laboratory medicine, IFCC plays a crucial role in setting international standards, organizing high-level professional forums, and publishing research. It promotes the development and collaboration of clinical laboratories worldwide, enhancing the accuracy, reliability, and comparability of laboratory tests to support better patient diagnosis and treatment. Since its founding in 1952, IFCC has grown to include members from 119 countries and regions, with over 50,000 expert members, making it one of the most influential organizations in the field.
 
Racing for Life, Wondfo remains committed to driving high-quality development through scientific innovation. The company will continue to promote collaborative efforts between industry, academia, and research globally, striving to make in-vitro diagnostic technologies serve global health more effectively and to make biotechnology benefit all.